Antimicrobial Pharmacology of Non-Antibiotic Drugs

Non-antibiotic drugs encompass a diverse array of agents originally developed for indications such as hyperlipidaemia, inflammation, pain management and mood disorders, yet they exhibit intrinsic or synergistic antimicrobial properties. Drug repurposing has revealed that statins, non-steroidal anti-inflammatory drugs (NSAIDs), local anaesthetics, phenothiazines, antidepressants, antiplatelet agents and polyphenols can inhibit bacterial growth, disrupt biofilms and modulate virulence. Mechanisms of action range from interference with cell-wall biosynthesis, membrane perturbation and efflux pump inhibition to attenuation of quorum-sensing circuits and suppression of toxin production. These non-traditional antimicrobials offer promising adjunctive strategies to counteract antibiotic resistance, reduce therapeutic costs and expedite clinical translation by leveraging known safety profiles. Recent research has focused on optimising pharmacokinetic–pharmacodynamic relationships, exploring targeted delivery to infection sites and identifying synergistic combinations with established antibiotics. This emerging field holds global significance for the management of chronic biofilm-related infections, topical wound care and pulmonary delivery in cystic fibrosis, while expanding the therapeutic arsenal against multidrug-resistant pathogens.

Research from Nature Portfolio

Recent studies have demonstrated the potential of simvastatin as a topical antibacterial agent. In vitro analyses revealed that simvastatin exerts broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and permeabilised Gram-negative pathogens. Proteomic and macromolecular synthesis assays indicated that simvastatin interferes with multiple biosynthetic pathways, notably inhibiting protein synthesis and reducing toxin production. Anti-biofilm experiments showed that simvastatin eradicates established staphylococcal biofilms and enhances the efficacy of conventional topical antimicrobials. A murine MRSA skin infection model confirmed significant reductions in bacterial load and inflammatory cytokines following topical simvastatin application. Collectively, this foundational work highlights the feasibility of repurposing a lipid-lowering agent for antimicrobial therapy and lays the groundwork for formulation-driven optimisation.

Antimicrobial Pharmacology of Non-Antibiotic Drugs publication trend

The graph below shows the total number of articles in antimicrobial pharmacology of non-antibiotic drugs across all publications each year (not limited to Nature Index journals).

Technical terms

Biofilm: A structured community of microbial cells encased in a self-produced polymeric matrix adherent to surfaces.

Efflux pump: A membrane protein complex that expels antimicrobial agents from bacterial cells, contributing to resistance.

Minimum inhibitory concentration (MIC): The lowest concentration of an agent that prevents visible growth of a microbe in vitro.

Quorum sensing: Cell–cell communication in bacteria that regulates gene expression in response to population density, often controlling virulence and biofilm formation.

Pharmacokinetics: The study of drug absorption, distribution, metabolism and excretion, determining bioavailability at target sites.

References

1. Antimicrobial Properties on Non-Antibiotic Drugs in the Era of Increased Bacterial Resistance. Antibiotics (2020).
2. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Scientific Reports (2015).
3. Polyphenols as Inhibitors of Antibiotic Resistant Bacteria—Mechanisms Underlying Rutin Interference with Bacterial Virulence. Pharmaceuticals (2022).
4. NSAIDs as a Drug Repurposing Strategy for Biofilm Control. Antibiotics (2020).
5. Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy (2018).